Barron F, et al. - In advanced-non-small cell lung cancer (NSCLC) patients with an epidermal growth factor receptor (EGFR)-sensitizing mutation treated with tyrosine kinase inhibitors (TKIs) (gefitinib, erlotinib and afatinib), researchers assessed the characteristics to progression such as clinical patterns of progression (dramatic, gradual, and local) with the prognosis. Factors at TKI progression related to a longer overall survival (OS) included pattern [gradual-progression (32.1), dramatic (19.5) and local (18.8 months)], and the time to progression to TKI [>12 months (38.5), 6-12 months (19.1), <6 months (9.6)]. Considering these factors, a subset of patients could be defined who could derive benefit from continued TKI therapy, as well as from local-ablative therapy in progression sites, particularly in patients without T790M or who lack access to third-generation TKI.